Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
News|Articles|May 31, 2019
- Pharmaceutical Technology\'s In the Lab eNewsletter-06-05-2019
- Volume 14
- Issue 6
Metrohm’s Acquisition of B&W Tek Boosts Spectroscopy Portfolio
Author(s)Pharmaceutical Technology Editors
Metrohm gains B&W Tek’s line of spectroscopy instruments as well as expertise and facilities.
Advertisement
The acquisition of B&W Tek, an instrumentation company specializing in photonics, laser, spectrometer, and chemometric technologies, by Metrohm, a manufacturer of high-precision analytical instruments, earlier in May 2019 boosts Metrohm’s spectroscopy portofolio. As of May 1, 2019, Metrohm USA and Metrohm Canada began selling B&W Tek mobile spectroscopy solutions.
The addition of the B&W Tek products complements Metrohm’s existing Raman and near-infrared (NIR) solutions for lab and process. The acquisition includes handheld 1064-nm Raman systems and portable Raman analyzers for laboratory and field use as well as solutions for laser-induced breakdown spectroscopy (LIBS). The B&W Tek products, which include NanoRam and NanoRam-1064, TacticID, i-Raman Prime, and QTRam, will maintain their respective branding during the transition.
In addition, Metrohm’s spectroscopy product development and manufacturing will expand with the addition of B&W Tek’s expertise and facilities. The company offers a complete line of analytical laboratory and process systems for titration, ion chromatography, electrochemistry, and spectroscopy.
Source: Metrohm
Articles in this issue
over 7 years ago
Cleaning Validation for Biologic Equipmentover 7 years ago
Automatic Pretreatment System for Cell Culture Media Analysisover 7 years ago
Portfolio of Tools to Advance Immunotherapyover 7 years ago
Knauer Offers New Separation Columns and Screening Servicesover 7 years ago
New Compound Discovered that Kills Antibiotic-Resistant Microbesover 7 years ago
FDA Publishes Guidance on Therapeutic Protein Biosimilarsover 7 years ago
NIH Awards Grants to Advance STI Vaccine Developmentover 7 years ago
Advancing Cell Therapy for Diabetesover 7 years ago
AstraZeneca, BenevolentAI Partner on AI for Drug DiscoveryAdvertisement
Related to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pharma Fundamentals: Digital Pathology in Drug Development, Part 1
2
PharmTech’s Weekly Roundup—September 25, 2026
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
5